Abstract
Aim and Methods: We conducted two studies in healthy male subjects to assess the effect on serum cortisol levels of the novel inhaled corticosteroid GW870086, dosed at 6 mg, 12 mg and 15 mg/day (dry powder inhaler; NCT00549497) for 3 days and 5 mg and 8.75 mg/day (nebules; NCT01160003) for 14 days.
Results: In the 3-Day Study, the greatest suppression of serum cortisol weighted mean (0-24 hour) of GW870086, compared with placebo, was observed on Day 1 (29% suppression at the 15 mg dose). In the 14-Day Study, the greatest suppression was 15% for GW870086 5 mg. None of these values was considered clinically significant. After 3 days’ dosing, GW870086 was absorbed slowly (tmax: 0.8-3.5 hours) and eliminated with a t1/2 of 22.7 hours; the highest systemic exposure (AUC) was 26.7 ng.hour/mL. After 14 days, GW870086 tmax was 0.3-0.4 hours and t1/2 25.0-29.6 hours; the highest AUC was 16.7 ng.hour/mL. No safety issues were identified in these studies.
Conclusion: At estimated therapeutic and supratherapeutic doses, which achieved high exposure (AUC) in both studies, GW870086 did not exhibit the usual level of hypothalamic-pituitary-adrenal axis suppression that would be expected with traditional inhaled corticosteroids.
Keywords: Cortisol, GW870086, pharmacokinetics, safety.
Current Drug Therapy
Title:Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GW870086: Two Randomised Studies
Volume: 8 Issue: 2
Author(s): Ann Allen, Philippe Bareille, Kelly Hardes and Jonathan Robertson
Affiliation:
Keywords: Cortisol, GW870086, pharmacokinetics, safety.
Abstract: Aim and Methods: We conducted two studies in healthy male subjects to assess the effect on serum cortisol levels of the novel inhaled corticosteroid GW870086, dosed at 6 mg, 12 mg and 15 mg/day (dry powder inhaler; NCT00549497) for 3 days and 5 mg and 8.75 mg/day (nebules; NCT01160003) for 14 days.
Results: In the 3-Day Study, the greatest suppression of serum cortisol weighted mean (0-24 hour) of GW870086, compared with placebo, was observed on Day 1 (29% suppression at the 15 mg dose). In the 14-Day Study, the greatest suppression was 15% for GW870086 5 mg. None of these values was considered clinically significant. After 3 days’ dosing, GW870086 was absorbed slowly (tmax: 0.8-3.5 hours) and eliminated with a t1/2 of 22.7 hours; the highest systemic exposure (AUC) was 26.7 ng.hour/mL. After 14 days, GW870086 tmax was 0.3-0.4 hours and t1/2 25.0-29.6 hours; the highest AUC was 16.7 ng.hour/mL. No safety issues were identified in these studies.
Conclusion: At estimated therapeutic and supratherapeutic doses, which achieved high exposure (AUC) in both studies, GW870086 did not exhibit the usual level of hypothalamic-pituitary-adrenal axis suppression that would be expected with traditional inhaled corticosteroids.
Export Options
About this article
Cite this article as:
Allen Ann, Bareille Philippe, Hardes Kelly and Robertson Jonathan, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GW870086: Two Randomised Studies, Current Drug Therapy 2013; 8 (2) . https://dx.doi.org/10.2174/15748855113089990004
DOI https://dx.doi.org/10.2174/15748855113089990004 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences Soy Isoflavone Alleviates Aβ1-42-Induced Impairment of Learning and Memory Ability Through the Regulation of RAGE/LRP-1 in Neuronal and Vascular Tissue
Current Neurovascular Research New Targeted Therapies for Anaplastic Thyroid Cancer
Anti-Cancer Agents in Medicinal Chemistry Nitric Oxide: A Key Mediator of Biofilm Dispersal with Applications in Infectious Diseases
Current Pharmaceutical Design Effect of Curcumin on Pro-angiogenic Factors in the Xenograft Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Pathophysiological Bases of Eosinophilic Esophagitis Therapy
Inflammation & Allergy - Drug Targets (Discontinued) Hereditary Haemorrhagic Telangiectasia (HHT): Genetic and Molecular Aspects
Current Pharmaceutical Design Overlooked Issues of Snakebite Management: Time for Strategic Approach
Current Topics in Medicinal Chemistry Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
Current Drug Targets Drug Delivery from Therapeutic Self-Assembled Monolayers (T-SAMs) on 316L Stainless Steel
Current Topics in Medicinal Chemistry Coupling the Inhibition of Viral Transduction with a Positive Fluorescence Signal
Combinatorial Chemistry & High Throughput Screening Neuropeptides and Gastric Mucosal Homeostasis
Current Topics in Medicinal Chemistry Crosstalk between Microglia and Neurons in Neurotrauma: An Overview of the Underlying Mechanisms
Current Neuropharmacology Baculovirus Gene Delivery: A Flexible Assay Development Tool
Current Gene Therapy Bronchopulmonary Dysplasia: An Imbalance of Inflammation
Current Respiratory Medicine Reviews Monocyte Adhesion in Atherosclerosis: A Biomechanical Approach
Vascular Disease Prevention (Discontinued) Contribution of Reactive Oxygen Species to Cartilage Degradation in Rheumatic Diseases: Molecular Pathways, Diagnosis and Potential Therapeutic Strategies
Current Medicinal Chemistry Bradykinin B2 receptors play a neuroprotective role in Hypoxia/reoxygenation injury related to pyroptosis pathway
Current Neurovascular Research Sodium Hydrosulfide Attenuates Beta-Amyloid-Induced Cognitive Deficits and Neuroinflammation via Modulation of MAPK/NF-κB Pathway in Rats
Current Alzheimer Research Mitochondria Sentencing About Cellular Life and Death: A Matter of Oxidative Stress
Current Pharmaceutical Design